Stock Code: China National Medicines Corporation Ltd(600511) stock abbreviation: China National Medicines Corporation Ltd(600511) Announcement No.: pro 2022006 China National Medicines Corporation Ltd(600511)
Announcement on 2021 profit distribution plan
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Distribution ratio: cash dividend of 7.0 yuan (including tax) for every 10 shares. The plan of converting capital reserve into share capital will not be implemented.
The profit distribution is based on the total share capital registered on the equity distribution registration date, and the specific date will be specified in the equity distribution implementation announcement.
If the total share capital of the company changes before the equity registration date of equity distribution, it is proposed to maintain the total distribution unchanged, adjust the distribution proportion per share accordingly, and make a separate announcement on the specific adjustment. 1、 Contents of profit distribution plan
Audited by Ernst & Young Huaming Certified Public Accountants (special general partnership), China National Medicines Corporation Ltd(600511) in 2021, the net profit attributable to the owner of the parent company was 175408421880 yuan (as of December 31, 2021, the cumulative amount of the company’s statutory surplus reserve had reached more than 50% of the registered capital, so it was no longer withdrawn), The distributable profit attributable to the parent company in this year is 175408421880 yuan.
In combination with the relevant provisions of the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies No. 1 – standardized operation of Shanghai Stock Exchange and the actual needs of the company’s business development, the following profit distribution plan is made: the company plans to take the total share capital of 754502998 shares as the base on December 31, 2021, Cash dividends of 7.0 yuan (including tax) will be distributed for every 10 shares, with a total of 52815209860 yuan. The remaining undistributed profits will be carried forward to the next year. The plan of converting capital reserve into share capital will not be implemented. The proportion of cash dividends of the company in this year accounts for 30.11% of the net profit of that year.
If the total share capital of the company changes between the date of disclosure of this announcement and the date of equity distribution and equity registration, it is proposed to maintain the total distribution unchanged, adjust the distribution proportion per share accordingly, and make a separate announcement on the specific adjustment.
The profit distribution plan needs to be submitted to the general meeting of shareholders for deliberation.
2、 Decision making procedures performed by the company
(I) convening, deliberation and voting of the board meeting
The profit distribution plan was approved at the 37th meeting of the seventh board of directors held on March 16, 2022. The profit distribution plan needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
(II) opinions of independent directors
The independent directors of the company checked and reviewed the company’s 2021 profit distribution and capital reserve conversion to share capital plan (plan) in accordance with the relevant provisions of the CSRC’s guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies on Shanghai stock exchange No. 1 – standardized operation, the articles of association and so on, The independent opinions are as follows:
The company’s profit distribution plan for 2021 complies with the relevant provisions of the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies on Shanghai Stock Exchange No. 1 – standardized operation, the articles of association and other relevant provisions of the CSRC, conforms to the actual situation of the company, and does not harm the interests of shareholders, especially small and medium-sized shareholders.
(III) opinions of the board of supervisors
The board of supervisors of the company checked and reviewed the company’s 2021 profit distribution and capital reserve conversion to share capital scheme (plan) in accordance with the relevant provisions of the CSRC, the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies No. 1 – standardized operation of Shanghai Stock Exchange, the articles of association and so on, The opinions are as follows: the distribution proportion, distribution form and decision-making procedure of the company’s profit distribution plan for 2021 comply with relevant regulations. This profit distribution plan fully considers the company’s profitability, future development capital demand, shareholder return and other factors, and there is no situation that damages the interests of the company and minority shareholders.
3、 Relevant risk tips
This profit distribution plan combines the company’s development stage, future capital demand and other factors, and will not have a significant impact on the company’s operating cash flow, nor will it affect the company’s normal operation and long-term development.
The profit distribution plan can only be implemented after being submitted to the 2021 annual general meeting of shareholders of the company for deliberation and approval.
It is hereby announced.
China National Medicines Corporation Ltd(600511) March 17, 2022
